Editorial: Decernotinib: A Next‐Generation Jakinib

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Arthritis & Rheumatology

• Publication date

  2016-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.39463PMID 26479275PMCID PMC5026186
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

  2016influential reference
• The JAK-STAT pathway: impact on human disease and therapeutic intervention.

  2015cited by this paper
• Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡

  2015cited by this paper
• VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease

  2015cited by this paper
• Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.

  2015cited by this paper
• A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

  2015cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

  2014cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• Advances in kinase inhibition: treating rheumatic diseases and beyond

  2014cited by this paper
• JAKs and STATs in immunity, immunodeficiency, and cancer.

  2013cited by this paper
• Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*

  2013cited by this paper
• Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

  2013cited by this paper
• Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

  2008cited by this paper
• Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation.

  2007cited by this paper
• Jaks and STATs: biological implications.

  1998cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

  1995cited by this paper

• JAK-STAT pathway in hematological malignancies: Achievements, challenges and future perspectives.

  2026cites this paper
• Genetic Association of Juvenile Idiopathic Arthritis With Adult Rheumatic Disease

  2024cites this paper
• Ubiquitous Role of Phosphine‐Based Water‐Soluble Ligand in Promoting Catalytic Reactions in Water

  2024cites this paper
• Cu(II)/PTABS-Promoted, Regioselective SNAr Amination of Polychlorinated Pyrimidines with Mechanistic Understanding.

  2023cites this paper
• Nanoparticulate drug delivery systems for the treatment of rheumatoid arthritis: A comprehensive review

  2023cites this paper
• Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?

  2022cites this paper
• Topical VX-509 Attenuates Psoriatic Inflammation Through the STAT3/FABP5 Pathway in Keratinocytes.

  2022cites this paper
• Drug repurposing for rheumatoid arthritis: Identification of new drug candidates via bioinformatics and text mining analysis

  2022cites this paper
• Repurposing of gastric cancer drugs against COVID-19

  2021cites this paper
• The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions

  2021cites this paper
• The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis

  2021cites this paper
• The JAK/STAT signaling pathway: from bench to clinic

  2021cites this paper
• Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling

  2021cites this paper
• Management of Rheumatoid Arthritis: An Overview

  2021cites this paper
• Role of Janus Kinase Inhibitors in Therapy of Psoriasis

  2021cites this paper
• New era of therapy for endocrine autoimmune disorders

  2020cites this paper
• The role of JAK/STAT signaling pathway and its inhibitors in diseases.

  2020cites this paper
• Translating JAKs to Jakinibs

  2020cites this paper
• Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors

  2020cites this paper
• Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

  2020cites this paper
• JAK/STAT pathway in pathology of rheumatoid arthritis (Review)

  2020cites this paper
• Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors

  2020cites this paper
• Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses

  2020cites this paper
• JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

  2019cites this paper
• Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

  2019cites this paper
• Clinical efficacy of new JAK inhibitors under development. Just more of the same?

  2019cites this paper
• Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors

  2019cites this paper
• Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis

  2019cites this paper
• Are peptides a solution for the treatment of hyperactivated JAK3 pathways?

  2019cites this paper
• Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

  2019cites this paper
• The role of the JAK/STAT signal pathway in rheumatoid arthritis

  2018cites this paper
• JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

  2017influential citation
• JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

  2017cites this paper
• Filgotinib for the treatment of rheumatoid arthritis

  2017cites this paper
• Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.

  2017cites this paper
• Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?

  2017cites this paper
• Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

  2017cites this paper